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Background: The prevalence of type 2 diabetes is increasing at an alarming rate in developing countries. However,
glycaemia control remains suboptimal and insulin use is low. One important barrier is the lack of an efficient and
effective insulin initiation delivery approach. This study aimed to document the strategies used and proposed by
healthcare professionals to improve insulin initiation in the Malaysian dual-sector (public–private) health system.
Methods: In depth interviews and focus group discussions were conducted in Klang Valley and Seremban, Malaysia
in 2010–11. Healthcare professionals consisting of general practitioners (n = 11), medical officers (n = 8), diabetes
educators (n = 3), government policy makers (n = 4), family medicine specialists (n = 10) and endocrinologists (n = 2)
were interviewed. We used a topic guide to facilitate the interviews, which were audio recorded, transcribed
verbatim and analysed using a thematic approach.
Results: Three main themes emerged from the interviews. Firstly, there was a lack of collaboration between the
private and public sectors in diabetes care. The general practitioners in the private sector proposed an integrated
system for them to refer patients to the public health services for insulin initiation programmes. There could be
shared care between the two sectors and this would reduce the disproportionately heavy workload at the public
sector. Secondly, besides the support from the government health authority, the healthcare professionals wanted
greater involvement of non-government organisations, media and pharmaceutical industry in facilitating insulin
initiation in both the public and private sectors. The support included: training of healthcare professionals;
developing and disseminating patient education materials; service provision by diabetes education teams;
organising programmes for patients’ peer group sessions; increasing awareness and demystifying insulin via public
campaigns; and subsidising glucose monitoring equipment. Finally, the healthcare professionals proposed the
establishment of multidisciplinary teams as a strategy to increase the rate of insulin initiation. Having team
members from different ethnic backgrounds would help to overcome language and cultural differences when
communicating with patients.
Conclusion: The challenges faced by a dual-sector health system in delivering insulin initiation may be addressed
by greater collaborations between the private and public sectors and governmental and non-government
organisations, and among different healthcare professionals.
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The United Kingdom Prospective Diabetes Study (UKPDS)
has found that intensification of glycaemic control prevents
and delays diabetes-related complications [1]. This often
requires oral glucose-lowering drugs in addition to lifestyle
modification. However, because of progressive insulin de-
pletion, the majority of patients with type 2 diabetes will
require insulin to achieve optimal glycaemic control 5–10
years after diagnosis [1,2]. Internationally, most studies
found only about 26–34% of patients with type 2 diabetes
achieved optimal glycaemic control [3-6]. This could be
related to low employment of an insulin regimen [3,7,8].
In Malaysia, the prevalence of type 2 diabetes ranks
seventh in the world [9] and is the highest in the West-
ern Pacific region [10]. A recent study found that 81.9%
of Malaysian adults with diabetes seen at the primary
care setting did not achieve the recommended glycaemic
goal of less than 6.5% haemoglobin A1c [11]. One im-
portant reason for poor glycaemic control is the delay in
initiating and intensifying insulin therapy [12]. In Malaysia,
studies have reported very low usage of insulin among
patients with type 2 diabetes [11,13].
Many factors contribute to the delay in insulin initiation
in clinical practice: patient factors, such as psychological
insulin resistance; clinician factors, such as lack of training
and confidence; and system factors. Common system bar-
riers include: short consultation times, rapid staff turnover
and lack of continuity of care [14], and these barriers vary
across different health systems. Malaysia has a dual-sector
healthcare system comprising public (government subsi-
dised) and private (fee for service) sectors. Almost three-
quarters of patients with diabetes are managed in the public
sector, which often has a high patient load and turnover of
doctors [13]. Furthermore, patients in the public sector
are often not given a choice of which doctor they would
prefer to consult. Therefore, to improve optimisation of
glycaemic control and update of insulin, effective and effi-
cient strategies are needed, particularly those targeting the
healthcare delivery system. This study aimed to explore
the views of Malaysian healthcare professionals (HCPs) on
the strategies that would facilitate insulin initiation among
patients with type 2 diabetes.
Methods
Design
We conducted semi-structured interviews and focus
group discussions with HCPs to explore the strategies they
used or proposed to improve service delivery in order to
facilitate insulin initiation. A qualitative methodology
allowed us to explore views on healthcare delivery systems
related to the practise of insulin initiation in local practice
situations [15]. This also enabled us to have a more holis-
tic view of service delivery and strategies for its improve-
ment [16,17].HCPs participating in the focus group discussion were
grouped according to their practice background and lo-
cation. This was to ensure homogeneity and to capitalise
on shared experiences among the HCPs [18]. For logistic
reasons, we conducted individual in-depth interviews
with key opinion leaders, such as government policy
makers. The use of in-depth interviews, focus group dis-
cussions and field notes served to triangulate of the data.
Setting
In Malaysia, insulin therapy is initiated by HCPs from
government hospitals and health clinics; university-based
hospitals and primary care clinics; and private hospitals
and general practice clinics. In this study, we recruited
the HPCs from three states (Wilayah Federal Territory,
Negeri Sembilan and Selangor) and from both urban
and semi-rural locations. Two key policy makers from
the Ministry of Health who were involved in developing
and implementing the national diabetes strategic plan
were also interviewed.
Participants, recruitment and sampling
Recruitment was done by researchers. We used purpos-
ive sampling to identify the stakeholders who were
involved in insulin initiation. They comprised family
medicine specialists, general practitioners (GPs), govern-
ment medical officers and diabetes nurse educators,
endocrinologists and government policy makers. We
used the ‘snowballing’ technique to recruit participants
by asking stakeholders to identify individuals and organi-
sations who were involved in insulin initiation. Some
GPs chose not to participate in the study. The reasons
were that they were either not interested in research or
they perceived that the interviews would disrupt their
clinical work as they ran solo practices. We interviewed
and analysed in an iterative manner until no new themes
emerged. The recruitment was stopped when research-
ers discussed and reached consensus that the analysis
had reached thematic saturation.
Data collection
An interview topic guide was developed based on literature
review and expert opinion. The questions in the topic guide
were based on the conceptual framework where health care
professionals, patients and the health care delivery system
are factors that may influence the initiation of insulin [14].
We interviewed the HCPs using open-ended questions and
used prompts only if important issues did not emerge
spontaneously during the interview. The HCPs were
informed that the interview focused on patients with type 2
diabetes who are indicated to start insulin. The HCPs were
asked about the barriers, facilitators and their experience of
insulin initiation and this has been reported else [19]. They
were also asked to suggest strategies they used or would
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researchers conducted the individual interviews and focus
groups using the topic guide.
We sought written consent from all the participants
for audio-recording and the interviews. The participants
were informed about the anonymity and the confidentiality
of the interview.
An assistant took field notes on non-verbal cues and inter-
view dynamics. Between October, 2010, and May, 2011, we
conducted individual interviews and focus groups, lasting
about 30 and 60 minutes, respectively. We reached data
saturation after ten individual interviews and four focus
groups. All the interviews were audio recorded, transcribed
verbatim and the transcripts were used as data for analysis.Data analysis
A thematic analysis approach was used. The themes
were derived inductively from the data. The researchers
familiarised themselves with the data by reading and re-
reading the transcripts. Three researchers coded two
transcripts (interviews with a primary-care physician and
a government policy maker) independently and a list of
free nodes (themes) was created. The free nodes were
merged to form larger categories. This framework, con-
sisting of categories and themes, was used subsequently
to code (label) another two transcripts by the researchers
independently. The coding was then compared for inter-
rater consistency and any discrepancies were resolved by
discussion. Attempts were made to reach a consensus,
and in the event that disagreement occurred, an independ-
ent researcher (who did not participate in the analysis)
would be asked to analyse the data separately. However,
this situation did not arise in this study. Consensus was
reached on the final list of nodes and their descriptions.
This final list of revised nodes was imported into Nvivo9
software and served as the framework for coding the rest
of the transcripts. New themes that were identified were
added to the list upon consultation with the research
team. The quotes were chosen based on their representa-
tiveness of the themes that emerged from the transcripts.
We screened through all the quotes and extracted those
that best captured the essence of the themes.
Negative cases were included in the analysis and high-
lighted to explain why the individual’s views were different
from the majority. For example, unlike most GPs, one par-
ticipant did not have problem initiating insulin with his
patients. We explored and realised that he had a special
interest in managing diabetes foot and most of his patients
presented with complications of diabetes. This highlighted
the context of his practice was different from the rest.
Two of the researchers (CJN and PYL) are family medi-
cine specialists and the third is a postgraduate psycholo-
gist (YKL). The researchers were conscious of theirpersonal and professional views on insulin initiation. The
team underwent constant reflection and open discussion
throughout the interviews and analysis to reduce possible
biases. This study was part of a larger 3-year study that
aimed to develop a patient decision aid for people with
type 2 diabetes who are considering insulin therapy.
Ethics approval
This study received ethics approval from the University
of Malaya Medical Centre Medical Ethics Committee
and the Medical Research and Ethics Committee of the
Ministry of Health, Malaysia.
Results
Characteristics of the participants
A total of 38 HCPs participated in the study: 11 general
practitioners, ten family medicine specialists, eight medical
officers, four government policy makers, three diabetes
educators and two endocrinologists. Of the 38 HCPs, 24
were from the government sector and 14 from the private
sector. Their mean age was 47 years (range 30–66 years).
There were 29 women and nine men; and 13 Malays, 12
Indians, 10 Chinese and three other races.
Three main strategies to improve insulin initiation
emerged from the data: (1) collaboration between the
public and private sector; (2) greater involvement of
pharmaceutical industry, media and non-government
organisations (NGOs); and (3) establishment of multidis-
ciplinary teams.
Collaboration between the public and private sector
Doctors from the private sector lacked resources to initi-
ate insulin. Therefore, HCPs suggested that the govern-
ment medication subsidies be made available to patients
on diabetes follow-up at private facilities. The public sec-
tor, on the other hand, faced the problem of a heavy
workload and limited consultation time. Shared care be-
tween the public and the private sectors would help to
overcome the barrier of limited consultation time in the
public sector.
“The Government should set aside a fund, where. . . it’s
not that only poor people should do this thing, I think
it should be sort of like. . . we GPs have no backup.
(Government should set aside a fund to be used by
private sector GPs for people treated by GPs; currently
these GPs have no backup) They should let us, maybe
with the patient’s IC (identity card), prove ourselves
that our patients are diabetic, and we should at least
be able to get the needles and some basic things from
the Ministry.” (GP, private practice)
“. . . like my patients I see from the hospitals, they are
going to the Klinik Kesihatans (Government Health
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blame the doctors, because how much time do they
have in contact with the patients? So there should be a
sharing treatment on diabetics with private clinics
where they should be able to see these doctors and the
Government should subsidize their treatment or
something, ok in 6 months time you go back here, get
your thing, but other times go and visit your nearest
clinic, GP clinic, where they can spend more time with
you.” (GP, private practice)
In the private sector, most general practitioners did
not have supporting staff such as diabetic educators and
dieticians to provide patient education. One option was
to enrol their patients for diabetes education in the govern-
ment health clinics.
“I mean the Government has a lot of budget for many
mega-projects, . . . and I think there should be some
kind of subsidy (patient education) program when GPs
can participate. . . . It shouldn’t just be limited to the
hospital. The participation should be open to the GPs.”
(GP, private practice)
Greater involvement of pharmaceutical industry, media
and non-government organisations
Pharmaceutical industry
Pharmaceutical companies could play an important role
in continuing medical education by organising training
and workshops on insulin initiation for HCPs.
“So, that is actually with the help of some educational
grant, there’s been a lot of help from the pharma
industry.....they have also given a grant to run the
workshops . . .” (Endocrinologist, government hospital)
Pharmaceutical representatives may act as a resource
person to support the doctors in starting their patients
on insulin. Unlike medical colleagues, the pharmaceutical
representatives spent time with the GPs and guided them
through the insulin initiation process step-by-step.
“The pharma companies, they have been very good, so
the guy will come with every literature to me, he will
train me up, and then I will say, oh, so many units,
what if the patient goes into hypo (hypoglycaemia), and
then they will have to convince me, doctor, they are not
going to go into hypo. We believe in that because we are
going to start with a very low dose, these drugs are very
different from the old insulin. So they are holding my
hand, and they have guided me to use insulin......so I
have learnt my insulin not through any endocrinologist,
not through any doctor, but these guys. . . they walk the
talk, walk the talk with me.” (GP, private practice)In the government sector, pharmaceutical companies
were involved in providing patient educational and deci-
sion support material, which healthcare providers used
when helping a patient to make decisions about initiating
insulin. Most of the patient health education materials on
insulin were developed and provided by the pharma-
ceutical companies.
“Decision maps like those provided by Pharmaceutical
Company A, that kind of thing. Some clinics have
started doing that, erm. . . it is something which we
supported, but I’m not sure how many clinics are
motivated enough to move, to want to organise. . . .I
see it as a good tool. I see it as a different approach to
health education.” (Government policy maker)
“That’s not the ‘in’ thing in Malaysia. Pharma. A lot
people are not comfortable. For me, as long as it’s not
biased. You know. This one (guide book) for example,
this is supported. . . printing supported by
Pharmaceutical Company B. . .(I) have to source for the
fund. The ministry don’t want to pay. I think, that it’s a
bit ridiculous. I asked Pharmaceutical Company B, I
asked around, I asked Pharmaceutical Company C,
Company C don’t want.” (Government policy maker)
“So, that is actually with the help of some educational
grant, there’s been a lot of help from the pharma
industry, so even to develop this guide, it is actually
with the help of pharma. . .” (Endocrinologist,
government hospital)
The pharmaceutical industry also helped to supply insulin
pens to patients free of charge. In addition, in the private
sector, where there was a lack of resources, some pharma-
ceutical companies employed diabetes educators to assist
the doctors in educating patients about insulin therapy.
“For me I would talk to the company and tell them,
you make sure if you want me to use your insulin, you
had better supply enough pens for me.” (Family
Medicine Specialist, Government health clinic)
“You can get them (pharmaceutical companies). . .you
can just give them a call, and you have a certain
patient you think has to be on insulin, and that
patient refuses to take the insulin in spite you have
informed him, and you find resistance. And you can
get these people, these people who market you this
insulin, they will do the marketing for you. They will
go to the house; they’ll talk to the patient. I had one
patient who had a problem, but after about 5 months
the patient finally accepted to take insulin. (GP,
private practice)
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Some HCPs felt that the media played an important role
in educating the public about diabetes and the benefits
of insulin.
“I feel the media should play a part. An important
role. Like, you know, a TV channel. . . Just every day,
two, three times say, 5 minutes, what is diabetes, how
important it is, how insulin is important. . . Because
every day we all see the TV, in Tamil, or Malay, or
Chinese, or English. . . if they put every day 5 minutes
of time out, three times a day, I think people will
think, you know, these are the psychological feelings,
every day goes to the mind and they come to think of
it.” (GP, private practice)
Non-government organisations
NGOs could be involved in organisation of conferences
for training of HCPs in education and counselling of
patients with diabetes.
“. . .health counselling or health education delivery.
Erm. . . Prof Prochaska’s, transtheoretical model, he
came to Malaysia last year. So, there was a diabetes
conference, erm. . . held by the erm, the Diabetes
Education arm of, educators arm, of Persatuan
Diabetes Malaysia (Malaysia Diabetes Association)
. . ..” (Government policy maker)
When facing time constraints and lack of expertise,
some doctors from the private sector felt that NGOs
could help by providing a dietetic service and by en-
gaging diabetes educators to counsel patients about in-
sulin therapy.
“. . .behind (my clinic) there’s diabetic centre of
Malaysia. . . The diabetes centre is just behind. So if
they actually need some further explanation, just go
round the corner . . .that’s for my area. And then
there’s also the nutrition specialist, they have full diet
(full dietary advice) and everything they will. . .can be
referred. So in our locality, quite easy.” (GP, private
practice)
Other important roles of NGOs included organising
peer support group sessions, health screening and road
shows; and subsidising glucometers, strips and needles
for patients with diabetes.
“We have two big NGOs for diabetes, which is
um. . .the PDM, Malaysian Diabetes Association and
then NADI, the National Diabetes Institute. So in
terms of patient support, um. . .you know I
mean. . .PDM is good in the sense that it gives patientsthe facilities to get uh. . .you know. . .I mean, at cost
price all the equipment, test strips, meters and. . .and
they have very good network, branches all over the
country. So, they’re actually helping patients. . . .they
are developing patient support material and then they
go for road shows for screening, public screening, the
usual thing.” (Endocrinologist, government hospital)
Multidisciplinary team
The HCPs suggested that setting up multidisciplinary
teams, consisting of doctors, assistant medical officers,
diabetic educators, nurses, pharmacists and dieticians,
would greatly facilitate insulin initiation. However, infor-
mation provision should be consistent to avoid giving
contradictory advice. The involvement of other health-
care team members could overcome the time constraints
of doctors to counsel patients.
“. . .ermm, forming a multidisciplinary team. Although
probably not a complete team like they have in the
hospital, but at least you should have a nurse, a
medical officer, a specialist will not be available in our
clinic. And then the pharmacist actually can be
involved in the team so that everybody should be
having a role and then of course you have to make
sure that these people understand each others’ roles
and are giving similar information.” (Family Medicine
Specialist, government health clinic)
“Uh, in the way there’s short of time, the patient lack
of counselling, so I have to get somebody, the
counselling nurse, to do the counselling. So those are
uncontrolled they will send to the nurse, the nurse will
try to talk to the patient and talk about diet, exercise,
all those stuff. And then uh they will go back and take
their medicine and go. So, with the counselling nurse
on and then subsequently the pharmacists, uh, it can
improve a bit. I think for the doctor it’s very difficult
for the MOs (medical officers) to do the talking. They
have no time to talk, basically.” (Family Medicine
Specialist, government health clinic)
To overcome the problem of short consultation time
and fast turnover of doctors in the government clinics,
policy makers advocated the empowerment of paramed-
ical staff to counsel patients with diabetes who needed
insulin. The proposed strategies included a reference
guide and training programmes targeted at the allied
health workers.
“Policy level, I feel, although the paramedics can’t
prescribe, I feel that they actually can play a big role in
influencing patient's decision, whether they want it or
not, how empowered are they to. . . to. . . self-titrate, or
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are the constant figure in that particular clinic, the
doctors come and go. So, I’m keen actually, for this, for
example, for the insulin to come out with the quick
reference to teach the paramedics as well. These are the
things that can be done.” (Government policy maker)
The HCPs emphasised the importance of teamwork in
helping patients to control their diabetes and to advise
them on insulin initiation.
“Hmm. . . so that’s why our arrangement there. . .
before the doctor sometimes sees us first, then we
educate them. . .ha. . . so we explain to them what they
should do, should increase which medicine, why sugar
levels are high, why sugar levels are low, what. . .hmm. . .
things like that. . . so teamwork is always better.”
(Diabetic educator, government university hospital)
“It should be. . .there must be a diabetic educator,
dietician. It should be a combined work, not only a
doctor who does this. There must be team play. A
team work to do this.” (GP, private practice)
Some doctors noted that having team members from
different ethnic backgrounds helped to overcome the
language barriers they face during consultations.
“. . .that uh language, I feel, is a very important barrier
you have to overcome. But anyhow with the help of my
MOH (Medical officer of Health)I manage to get, uh,
lots of Indian staff to be in the clinic. Even I got the
sister who’s Indian, I got the attendant who is Indian.
So, basically it when we improve the communication,
the patient can accept it (the treatment) better.”
(Family Medicine Specialist, government health clinic)Discussion
The finding from the study highlighted three main
strategies to improve insulin initiation in a dual-sector
health system: (1) collaboration between the public and pri-
vate sector; (2) greater involvement of pharmaceutical in-
dustry, media and non-government organisations (NGOs);
and (3) establishment of multidisciplinary teams.
The participants highlighted the uneven distribution of
resources for the management of chronic diseases such as
diabetes within the dual-sector healthcare system. The
government health clinics are facing a shortage of doctors
[20-22], and the rising incidence of type 2 diabetes will ag-
gravate the situation as the majority of patients with dia-
betes are managed in the public health sector. On the
other hand, most of the private GPs in Malaysia run solo
practices and they lack resources and support to initiateinsulin. The lack of integration and collaboration of the
dual-sector health system is a major barrier for insulin ini-
tiation in patients with diabetes. However, this dual-sector
healthcare system may provide a good opportunity to im-
prove the care of diabetes by utilising the strength of each
sector to integrate diabetic care. Studies by the World
Health Organisation and others have found that an inte-
grated health system can be effective in improving quality
of care [23,24]. Recently, a new national healthcare finan-
cing mechanism has been proposed to integrate the public
and private healthcare systems under the 9th Malaysia
Plan 2006–2010, and this includes the primary care ser-
vices [25-27]. This would help to reduce the existing dis-
crepancy in the distribution of resources and manpower
between the public and private sectors for diabetes care,
as emphasised by the HCPs in this study.
In this study, the HPCs also highlighted the role of the
pharmaceutical industry in providing HCP training and
diabetes educators to counsel patients. In recent years,
pharmaceutical companies have faced criticism [28-30] and
there are rising concerns about their influence on the
HCPs’ prescribing decisions [31,32]. Restricting contacts
between the pharmaceutical industry and HCPs could limit
open dialogue, hamper innovation and create a gap in edu-
cational support for HCPs, at least in developing countries
like Malaysia [33]. Moreover, collaboration may result in
mutual benefit for all parties, including health professionals,
the pharmaceutical industry and patients [34]. In the care
of diabetes and insulin initiation, the collaboration between
HCPs and the pharmaceutical industry in educational pro-
grammes and counselling for patients will eventually bene-
fit all parties. However, some regulations are needed to
prevent undue influence from the pharmaceutical com-
panies. Some countries have put in place processes, such
as the review and management of research, industry codes
of conduct, community responses and guidelines by prac-
titioner associations, to protect the interests of individual
patients and community interests [35-38]. This may also
help to foster research and the development of new pro-
ducts, maintain public confidence in pharmaceuticals and
medicine, and facilitate ethical decision making among
various stakeholders [35,39,40]. The Malaysian Govern-
ment and local professional bodies in the country may
need to develop more comprehensive regulations in rela-
tion to the involvement of pharmaceutical companies in
supporting health promotion programmes.
Non-profit, non-government health organisations play
an important role in providing counselling services and
support in terms of health education, peer group pro-
grammes and financial assistance to patients with diabetes
who need insulin initiation. Danika et al. reported that
non-profit organisation-sponsored programmes promot-
ing awareness about a disease or health condition are
more effective than those sponsored by a pharmaceutical
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importance of active collaborations between health con-
sumer organisations and the pharmaceutical industry [42].
The multidisciplinary team approach to diabetes care,
such as insulin initiation, is considered an essential step
towards improvement of patient care [43,44]. Besides im-
proving the efficiency of the diabetes service by reducing
the doctor’s consultation time, a multidisciplinary team
has been shown to improve glycaemic control, lower the
risk of diabetes complications, decrease health care costs
and improve patients’ quality of life [45,46]. As highlighted
by the HCPs in this study, a multidisciplinary team from
different ethnic backgrounds is crucial to overcome the
problem of language and cultural barriers, particularly
in a multi-ethnic country like Malaysia. In a review by
Caballero, increased cultural awareness and use of dia-
betes educators speaking the same language as the
patients improved acceptance of insulin therapy in
patients with type 2 diabetes [47]. Currently, in Malaysia,
the diabetes care teams are located mainly in the govern-
ment health care clinics or university primary care clinics
in urban areas. In the rural settings, many patients with
diabetes are managed by medical assistants, whose role is
mainly to prescribe, provide basic health education and
identify complications. In view of the benefits of a multi-
disciplinary team approach, Malaysia’s healthcare system
should empower the allied health workers, such as the
medical assistants, by continuously training and enhan-
cing their knowledge and skills on diabetes care, including
insulin initiation. This will reduce the healthcare burden
and cost without compromising patient care.
The strength of this study lies in the fact that the sam-
ple encompassed all healthcare sectors and stakeholders
who were involved in insulin initiation. We were thus
able to gather data from all levels of HCPs involved in
diabetes care. . This study also allows comparison of
views from the private and government HCPs in a dual-
sector health system, which may be applicable to other
developing countries with a similar health system.
The limitation of this study was that only HCPs’ per-
spectives were included and patients’ views were not
captured. The researchers are planning to conduct inter-
views with patients with type 2 diabetes who are consid-
ering insulin as part of a larger study. Besides that, as
the study was conducted in urban and semi-rural areas,
therefore the findings cannot be generalisable to rural
settings. Finally, two of the researchers are primary care
physicians (LPY and NCJ) and this may influence the in-
terpretation of the data. These potential biases are
reduced by constant reflection by the two researchers
about their roles and by involving an independent non-
clinician (LYK) in the analysis process.
Future research should look into how pharmaceutical
industry may be involved in educating the HCPs in theuse of insulin especially in resource-limited countries.
Secondly, the policy makers should develop strategies to
facilitate collaborations between public and private
health sectors especially in terms of how resources can
be shared more effectively.
Conclusions
The importance of integration and collaboration between
the public and private sectors, multidisciplinary teamwork
and active involvement of NGOs was considered as crucial
to improve service delivery for insulin initiation and dia-
betes care in Malaysia. The involvement of pharmaceutical
industry and NGOs may be important in the resource-
limited private sector. However, some regulations need to
put in place to prevent undue influence from the pharma-
ceutical industries on physicians’ clinical decisions. There-
fore, a proposed integration of the public and private
healthcare systems may help to make diabetes care, includ-
ing insulin initiation delivery, more effective and efficient.
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